Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

 Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

Shots:

  • The P-III KEYNOTE-522 study involves assessing of Keytruda + CT vs PBO + CT as neoadjuvant therapy, followed Keytruda vs PBO as adjuvant therapy in 1,174 patients in a ratio (2:1) with TNBC
  • The P-III KEYNOTE-522 study resulted in meeting its one of the dual 1EPs i.e, improvement in pCR rates regardless of PD-L1 status, safe and tolerable, no new safety signals were observed
  •  Keytruda is an anti-PD-1 therapy, blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activated T-lymphocytes affecting both tumor and healthy cells, being evaluated in three ongoing studies for TNBC (KEYNOTE-355, KEYNOTE-242 and KEYNOTE-522)

Click here to­ read full press release/ article | Ref: Merck | Image: LinkedIn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post